Skip to main content
. Author manuscript; available in PMC: 2016 Sep 1.
Published in final edited form as: Urol Oncol. 2015 Jan 22;33(9):387.e17–387.e27. doi: 10.1016/j.urolonc.2014.12.009

Table 2B.

Correlation of overexpression of CD62L with clinical outcome

Dataset Fold
change
Gene
Rank
Number of samples
(Dead, Alive)
P-value
Recurrence in superficial bladder cancers
Stransky – 2006 2.22 141 25 (22, 3)* 3.00 E-3
Dead at 1 yr in superficial bladder cancers
Blaveri -2005 1.67 291 19 (14, 5)
Dead at 3 yr in superficial bladder cancers
Blaveri -2005 1.89 94
*

(primary recurrence, recurrence)